The Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2023 to 2030 to reach $6.38 billion by 2030. Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost compared to Sanger sequencing. Continuous developments in NGS technology are revolutionizing the field of personalized medicine, genetic diseases, and clinical diagnostics by providing the capability to sequence multiple individuals with a variable genetic orientation simultaneously.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.
The prevalence of cancer is rising across the world. According to GLOBOCAN, in 2020, 9.5 million people were diagnosed with cancer in Asia–Pacific. This number is expected to rise to 12.3 million by 2030. The most common types of cancer are lung cancer, breast cancer, colon cancer, prostate cancer, and rectum cancer. According to the data published by the World Health Organization (WHO) in February 2022, cancer was among the most common cause of mortality all over the world. In 2020, it accounted for approximately 10 million deaths. Further, according to India Against Cancer, 2.7 million people were diagnosed with cancer in 2020.
The utilization of NGS is also growing in cancer treatment and research. NGS has been proven as an effective method for gaining a more precise and comprehensive understanding of the molecular foundations of individual cancers. Targeted medicines are quickly becoming the new standard of care for cancer. Also, NGS is currently starting to be used in clinical oncology to improve cancer therapy through a variety of techniques, including the discovery of novel and rare cancer mutations, the identification of cancer mutation carriers, and the development of specialized therapeutic approaches known as personalized medicine (PM). Further, NGS has the additional advantage of offering an expanded view of the disease landscape and revealing cancer development pathways. Thus, the rising cancer prevalence and increasing application of NGS in cancer treatment and research drive the demand for NGS in Asia–Pacific.
-Market.webp "Asia-Pacific Next Generation Sequencing (NGS) Market")
Click here to: Get Free Sample Pages of this Report
The Increasing Applications of NGS Create an Opportunity for the Market
NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers, which are consequently expected to increase the applications and usage of NGS technology, creating growth opportunities for the players operating in the NGS market.
The Consumables Segment is Expected to Account for the Largest Share of the Market in 2023
Among the offerings, in 2023, the consumables segment is expected to account for the largest share of the Asia–Pacific NGS market by offering. The recurring use of consumables, rising demand for NGS-based diagnostic tests, and increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery are increasing the demand for consumables.
The Targeted Genome Sequencing Segment is Expected to Account for the Largest Share of the Market in 2023
Among sequencing types, the targeted genome sequencing segment is expected to account for the largest share of the NGS market in 2023. The large share of this segment is attributed to rapid and cost-effective methods, applications in discovering somatic mutations in complex samples such as cancerous tumors mixed with germline DNA, and a high cult of researchers for targeted genome sequencing to study gene-drug associations is expected to drive the targeted genome sequencing segment.
The Sequencing by Synthesis Segment is Expected to Account for the Largest Share of the Market in 2023
Among the technologies, the sequencing by synthesis segment is expected to account for the largest share of the Asia–Pacific NGS market. The key factors supporting the large market share of this segment are highly accurate output with base-by-base sequencing using sequencing by synthesis, reducing sequence-specific errors, and enabling robust base calling across the entire genome, including repetitive sequences and homopolymers.
The Research and Other Applications is Expected to Account for the Largest Share of the Market in 2023
Among the applications, in 2023, the research and other applications segment is expected to account for the largest share of the Asia–Pacific NGS market. The growing prevalence of genetic disorders, the increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, and the increasing NGS-based research are factors contributing to the significant market share of this segment.
The Pharmaceutical & Biotechnology Companies Segment is Expected to Account for the Largest Share of the Asia–Pacific NGS Market in 2023
Among the end users, in 2023, the pharmaceutical & biotechnology segment is expected to account for the largest share of the Asia–Pacific NGS market. The large market share of this segment is attributed to factors such as the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of NGS among pharmaceutical & biotechnology companies.
China to Account for the Largest Market Share in 2023
In 2023, China is expected to account for the largest share of the Asia–Pacific NGS market. The large share is primarily attributed to the increasing government focus on sequencing projects, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, and growing research activities for developing personalized medicines.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years 2020–2023. The key players profiled in the Asia–Pacific NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).
Scope of the Report:
Asia–Pacific NGS Market Assessment, by Offering
Asia–Pacific NGS Market Assessment, by Sequencing Type
Asia–Pacific NGS Market Assessment, by Technology
Asia–Pacific NGS Market Assessment, by Application
Asia–Pacific NGS Market Assessment, by End User
Asia–Pacific NGS Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the Asia-Pacific NGS market, including the market size & forecast for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
The Asia-Pacific NGS market is projected to reach $6.38 billion by 2030, at a CAGR of 16.9% during the forecast period.
Among the offerings, the consumables segment is expected to account for the largest share of the Asia-Pacific NGS market. The large market share of this segment is attributed to the Recurring use of consumables, rising demand for NGS-based diagnostic tests, and increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery is increasing the demand for consumables.
In 2023, the targeted genome sequencing segment is expected to account for the largest share of the Asia-Pacific NGS market. The large market share of this segment is attributed to the highly accurate results, increasing demand for targeted genome sequencing, and low cost with high reliability.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, and increasing pharmaceutical R&D expenditures. Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities.
The key players profiled in the Asia-Pacific NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Cancer Prevalence and Increasing Application of NGS in Cancer Treatment and Research
4.2.2. The Declining Costs of Genome Sequencing
4.2.3. Technological Advancements in Sequencing Procedures
4.2.4. Increasing Pharmaceutical R&D Expenditures
4.3. Restraints
4.3.1. High Costs of NGS Systems and Consumables
4.3.2. Availability of Alternative Technologies
4.4. Opportunities
4.4.1. Increasing Applications of NGS
4.4.2. Rising Adoption of Bioinformatics and Genomic Data Management Solutions
4.4.3. Government Initiatives Supporting Large-scale Genomic Sequencing Projects
4.5. Challenges
4.5.1. Lack of Skilled Professionals
4.5.2. Regulatory and Standardization Concerns in Diagnostic Testing
4.6. Factor Analysis
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porter’s Five Forces Analysis
5. Asia–Pacific NGS Market Assessment—by Offering
5.1. Overview
5.2. Consumables
5.2.1. Sample Preparation Consumables
5.2.1.1. DNA Extraction and Amplification
5.2.1.2. Library Preparation & Target Enrichment
5.2.1.3. Quality Control
5.2.2. Other Consumables
5.3. NGS Platforms/Instruments
5.4. Software
5.5. Services
6. Asia–Pacific NGS Market Assessment—by Sequencing Type
6.1. Overview
6.2. Targeted Genome Sequencing
6.3. Whole Genome Sequencing
6.4. Whole Exome Sequencing
6.5. Other Sequencing Types
7. Asia–Pacific NGS Market Assessment—by Technology
7.1. Overview
7.2. Sequencing by Synthesis
7.3. Ion Semiconductor Sequencing
7.4. Single-molecule Real-time Sequencing (SMRT)
7.5. Nanopore Sequencing
7.6. DNA nanoball sequencing
8. Asia–Pacific NGS Market Assessment—by Application
8.1. Overview
8.2. Research Applications
8.2.1. Drug Discovery
8.2.2. Agriculture & Animal Research
8.2.3. Other Research Applications
8.3. Clinical Applications
8.3.1. Reproductive Health Diagnosis
8.3.2. Oncology
8.3.3. Infectious Diseases
8.3.4. Other Clinical Applications
9. Asia–Pacific NGS Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Hospitals and Diagnostic Laboratories
9.4. Academic Institutes and Research Centers
9.5. Other End Users
10. Asia–Pacific NGS Market Assessment—by Country
10.1. Overview
10.2. China
10.3. Japan
10.4. India
10.5. Australia
10.6. Singapore
10.7. Malaysia
10.8. New Zealand
10.9. Rest of Asia-Pacific (RoAPAC)
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Rankings, By Key Players (2022)
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Thermo Fisher Scientific Inc.
12.2. Illumina, Inc.
12.3. Qiagen N.V.
12.4. F. Hoffmann-La Roche Ltd
12.5. PerkinElmer, Inc.
12.6. Agilent Technologies, Inc.
12.7. Pacific Biosciences of California Inc.
12.8. Danaher Corporation
12.9. Bio-Rad Laboratories, Inc.
12.10. Oxford Nanopore Technologies Plc.
12.11. 10X Genomics, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Asia–Pacific: NGS Market, by Country/Region, 2021–2030 (USD Million)
Table 2 Asia–Pacific: NGS Market, by Offering, 2021–2030 (USD Million)
Table 3 Asia–Pacific: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 4 Asia–Pacific: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 5 Asia–Pacific: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 6 Asia–Pacific: NGS Market, by Technology, 2021–2030 (USD Million)
Table 7 Asia–Pacific: NGS Market, by Application, 2021–2030 (USD Million)
Table 8 Asia–Pacific: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 9 Asia–Pacific: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 10 Asia–Pacific: NGS Market, by End User, 2021–2030 (USD Million)
Table 11 China: NGS Market, by Offering, 2021–2030 (USD Million)
Table 12 China: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 13 China: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 14 China: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 15 China: NGS Market, by Technology, 2021–2030 (USD Million)
Table 16 China: NGS Market, by Application, 2021–2030 (USD Million)
Table 17 China: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 18 China: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 19 China: NGS Market, by End User, 2021–2030 (USD Million)
Table 20 Japan: NGS Market, by Offering, 2021–2030 (USD Million)
Table 21 Japan: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 22 Japan: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 23 Japan: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 24 Japan: NGS Market, by Technology, 2021–2030 (USD Million)
Table 25 Japan: NGS Market, by Application, 2021–2030 (USD Million)
Table 26 Japan: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 27 Japan: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 28 Japan: NGS Market, by End User, 2021–2030 (USD Million)
Table 29 India: NGS Market, by Offering, 2021–2030 (USD Million)
Table 30 India: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 31 India: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 32 India: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 33 India: NGS Market, by Technology, 2021–2030 (USD Million)
Table 34 India: NGS Market, by Application, 2021–2030 (USD Million)
Table 35 India: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 36 India: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 37 India: NGS Market, by End User, 2021–2030 (USD Million)
Table 38 Australia: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 39 Australia: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 40 Australia: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 41 Australia: NGS Market, by Technology, 2021–2030 (USD Million)
Table 42 Australia: NGS Market, by Application, 2021–2030 (USD Million)
Table 43 Australia: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 44 Australia: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 45 Australia: NGS Market, by End User, 2021–2030 (USD Million)
Table 46 Singapore: NGS Market, by Offering, 2021–2030 (USD Million)
Table 47 Singapore: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 48 Singapore: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 49 Singapore: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 50 Singapore: NGS Market, by Technology, 2021–2030 (USD Million)
Table 51 Singapore: NGS Market, by Application, 2021–2030 (USD Million)
Table 52 Singapore: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 53 Singapore: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 54 Singapore: NGS Market, by End User, 2021–2030 (USD Million)
Table 55 Malaysia: NGS Market, by Offering, 2021–2030 (USD Million)
Table 56 Malaysia: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 57 Malaysia: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 58 Malaysia: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 59 Malaysia: NGS Market, by Technology, 2021–2030 (USD Million)
Table 60 Malaysia: NGS Market, by Application, 2021–2030 (USD Million)
Table 61 Malaysia: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 62 Malaysia: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 63 Malaysia: NGS Market, by End User, 2021–2030 (USD Million)
Table 64 New Zealand: NGS Market, by Offering, 2021–2030 (USD Million)
Table 65 New Zealand: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 66 New Zealand: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 67 New Zealand: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 68 New Zealand: NGS Market, by Technology, 2021–2030 (USD Million)
Table 69 New Zealand: NGS Market, by Application, 2021–2030 (USD Million)
Table 70 New Zealand: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 71 New Zealand: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 72 New Zealand: NGS Market, by End User, 2021–2030 (USD Million)
Table 73 Rest of Asia-Pacific: NGS Market, by Offering, 2021–2030 (USD Million)
Table 74 Rest of Asia-Pacific: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 75 Rest of Asia-Pacific: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 76 Rest of Asia-Pacific: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 77 Rest of Asia-Pacific: NGS Market, by Technology, 2021–2030 (USD Million)
Table 78 Rest of Asia-Pacific: NGS Market, by Application, 2021–2030 (USD Million)
Table 79 Rest of Asia-Pacific: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 80 Rest of Asia-Pacific: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 81 Rest of Asia-Pacific: NGS Market, by End User, 2021–2030 (USD Million)
Table 82 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Asia-Pacific NGS Market, by Offering, 2023–2030 (USD Million)
Figure 8 Asia-Pacific NGS Market, by Sequencing Type, 2023–2030 (USD Million)
Figure 9 Asia-Pacific NGS Market, by Technology, 2023–2030 (USD Million)
Figure 10 Asia-Pacific NGS Market, by Application, 2023–2030 (USD Million)
Figure 11 Asia-Pacific NGS Market, by End User, 2023–2030 (USD Million)
Figure 12 Asia-Pacific NGS Market, by Country 2023–2030 (USD Million)
Figure 13 Impact Analysis: Asia-Pacific NGS Market
Figure 14 Market Dynamics: Asia-Pacific NGS Market
Figure 15 Asia-Pacific NGS Market, by Offering, 2023–2030 (USD Million)
Figure 16 Asia-Pacific NGS Market, by Sequencing Type, 2023–2030 (USD Million)
Figure 17 Asia-Pacific NGS Market, by Technology, 2023–2030 (USD Million)
Figure 18 Asia-Pacific NGS Market, by Application, 2023–2030 (USD Million)
Figure 19 Asia-Pacific NGS Market, by End User, 2023–2030 (USD Million)
Figure 20 Asia-Pacific NGS Market, by Country, 2023–2030 (USD Million)
Figure 21 Asia-Pacific NGS Market Snapshot
Figure 22 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 23 Asia-Pacific NGS Market: Vendor Dashboard
Figure 24 Asia-Pacific NGS Market: Competitive Benchmarking, by Offering
Figure 25 Asia-Pacific NGS Market: Competitive Benchmarking, by Sequencing Type
Figure 26 Market Share Analysis: Asia-Pacific NGS Market (2022)
Figure 27 Thermo Fisher Scientific, Inc.: Financial Snapshot, 2022
Figure 28 Illumina, Inc.: Financial Snapshot, 2022
Figure 29 Qiagen N.V.: Financial Snapshot, 2022
Figure 30 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2022
Figure 31 PerkinElmer, Inc.: Financial Snapshot, 2022
Figure 32 Agilent Technologies, Inc.: Financial Snapshot, 2022
Figure 33 Pacific Biosciences of California, Inc.: Financial Snapshot, 2022
Figure 34 Danaher Corporation: Financial Snapshot, 2022
Figure 35 Oxford Nanopore Technologies Plc.: Financial Snapshot, 2022
Figure 36 10X Genomics, Inc.: Financial Snapshot, 2022
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Nov-2023
Published Date: Aug-2023
